Proteomic differences among patients with heart failure taking furosemide or torsemide
Open Access
- 11 January 2022
- journal article
- research article
- Published by Wiley in Clinical Cardiology
- Vol. 45 (3) , 265-272
Abstract
Background: Loop diuretics are commonly used for patients with heart failure (HF) but it remains unknown if one loop diuretic is clinically superior.Hypothesis: Biomarkers and proteomics provide insight to how different loop diuretics may differentially affect outcomes.Methods: Blood and urine were collected from outpatients with HF who were taking torsemide or furosemide for >30 days. Differences were assessed in cardiac, renal, and inflammatory biomarkers and soluble protein panels using the Olink Cardiovascular III and inflammation panels.Results: Of 78 subjects, 55 (71%) were treated with furosemide and 23 (29%) with torsemide, and 25 provided a urine sample (15 treated with furosemide, 10 with torsemide). Patients taking torsemide were older (68 vs 64 years) with a lower mean eGFR (46 vs 54 ml/min/1.73 m2), a higher proportion were women (39% vs 24%) and Black (43% vs 27%). In plasma, levels of hs‐cTnT, NT‐proBNP, and hsCRP were not significantly different between groups. In urine, there were significant differences in urinary albumin, β‐2M, and NGAL, with higher levels in the torsemide‐treated patients. Of 184 proteins testing in Olink panels, in plasma, 156 (85%) were higher in patients taking torsemide but none were significantly different after correcting for false discovery.Conclusions: We show differences in urinary biomarkers but few differences in plasma biomarkers among HF patients on different loop diuretics. Olink technology can detect differences in plasma protein levels from multiple biologic domains. These findings raise the importance of defining differences in mechanisms of action of each diuretic in an appropriately powered study.Keywords
Funding Information
- National Heart, Lung, and Blood Institute (R01HL154768‐01)
This publication has 45 references indexed in Scilit:
- Effects of Prolonged-Release Torasemide Versus Furosemide on Myocardial Fibrosis in Hypertensive Patients with Chronic Heart Failure: A Randomized, Blinded–End Point, Active-Controlled StudyClinical Therapeutics, 2011
- Homogeneous antibody-based proximity extension assays provide sensitive and specific detection of low-abundant proteins in human bloodNucleic Acids Research, 2011
- Association of Serial Measures of Cardiac Troponin T Using a Sensitive Assay With Incident Heart Failure and Cardiovascular Mortality in Older AdultsJAMA, 2010
- Beneficial Effects of Torasemide on Systolic Wall Stress and Sympathetic Nervous Activity in Asymptomatic or Mildly Symptomatic Patients With Heart Failure: Comparison With AzosemideJournal of Cardiovascular Pharmacology, 2009
- Usefulness of C-Reactive Protein and Left Ventricular Diastolic Performance for Prognosis in Patients With Left Ventricular Systolic Heart FailureThe American Journal of Cardiology, 2008
- Effects of torasemide on cardiac sympathetic nerve activity and left ventricular remodelling in patients with congestive heart failureHeart, 2006
- Furosemide and the progression of left ventricular dysfunction in experimental heart failureJACC, 2004
- Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failureJACC, 2004
- Torasemide, but not frusemide, increases intracellular cAMP and cGMP content in the aorta of the renal hypertensive ratJournal of Pharmacy and Pharmacology, 1992
- Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics.Heart, 1987